Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

This phase 1 study sought to characterize the safety, tolerability, and pharmacokinetic behavior of VLX1570, a small molecule inhibitor of the deubiquitinases (DUBs) that remove sterically bulky ubiquitin chains from proteins during processing in the19S regulatory subunit of the proteasome, in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowinsky, Eric K., Paner, Agne, Berdeja, Jesus G., Paba-Prada, Claudia, Venugopal, Parameswaran, Porkka, Kimmo, Gullbo, Joachim, Linder, Stig, Loskog, Angelica, Richardson, Paul G., Landgren, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497669/
https://www.ncbi.nlm.nih.gov/pubmed/32125598
http://dx.doi.org/10.1007/s10637-020-00915-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497669/
https://www.ncbi.nlm.nih.gov/pubmed/32125598
http://dx.doi.org/10.1007/s10637-020-00915-4

Ejemplares similares